SLC30A8 and type 2 diabetes mellitus: Mice carrying SLC30A8 R138* showed a significant increase in insulin secretion with no changes to glucose and insulin tolerance (22, 23), implying that decreased β cell ZnT8 activity reduces T2D risk.